Matches in SemOpenAlex for { <https://semopenalex.org/work/W2088294678> ?p ?o ?g. }
Showing items 1 to 66 of
66
with 100 items per page.
- W2088294678 endingPage "140" @default.
- W2088294678 startingPage "139" @default.
- W2088294678 abstract "Commentary on: Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363:2499–510.[OpenUrl][1][CrossRef][2][PubMed][3][Web of Science][4] Venous thromboembolism (VTE) is a common and costly disorder. Limitations of current treatment options include the need for a multidrug regimen (parenteral and oral), labour-intensive monitoring and frequent adverse events. Rivaroxaban is an investigational, oral, direct factor Xa inhibitor. It provides effective VTE prevention in hip and knee replacement1,–,4 and stroke prevention in atrial fibrillation.5 This article reports the results of two rivaroxaban trials: treatment of acute deep vein thrombosis (DVT) and long-term treatment of DVT or pulmonary embolism (PE) after initial therapy. The acute DVT study is a randomised, open label non-inferiority trial comparing rivaroxaban with standard therapy for acute, symptomatic, proximal DVT. Participants received rivaroxaban 15 mg twice daily for 3 weeks, then … [1]: {openurl}?query=rft.jtitle%253DNew%2BEngland%2BJournal%2Bof%2BMedicine%26rft.stitle%253DNEJM%26rft.issn%253D0028-4793%26rft.volume%253D363%26rft.issue%253D26%26rft.spage%253D2499%26rft.epage%253D2510%26rft.atitle%253DOral%2Brivaroxaban%2Bfor%2Bsymptomatic%2Bvenous%2Bthromboembolism.%26rft_id%253Dinfo%253Adoi%252F10.1056%252FNEJMoa1007903%26rft_id%253Dinfo%253Apmid%252F21128814%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx [2]: /lookup/external-ref?access_num=10.1056/NEJMoa1007903&link_type=DOI [3]: /lookup/external-ref?access_num=21128814&link_type=MED&atom=%2Febmed%2F16%2F5%2F139.atom [4]: /lookup/external-ref?access_num=000285555600005&link_type=ISI" @default.
- W2088294678 created "2016-06-24" @default.
- W2088294678 creator A5011892370 @default.
- W2088294678 creator A5014841232 @default.
- W2088294678 date "2011-04-03" @default.
- W2088294678 modified "2023-09-27" @default.
- W2088294678 title "Oral rivaroxaban for acute DVT, or long term for VTE, is as effective as enoxaparin followed by a vitamin K antagonist for preventing recurrence, with no increase in bleeding complications" @default.
- W2088294678 cites W2014491911 @default.
- W2088294678 cites W2036506340 @default.
- W2088294678 cites W2118092611 @default.
- W2088294678 cites W2150567120 @default.
- W2088294678 cites W2151252098 @default.
- W2088294678 doi "https://doi.org/10.1136/ebm1301" @default.
- W2088294678 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21460399" @default.
- W2088294678 hasPublicationYear "2011" @default.
- W2088294678 type Work @default.
- W2088294678 sameAs 2088294678 @default.
- W2088294678 citedByCount "2" @default.
- W2088294678 countsByYear W20882946782012 @default.
- W2088294678 crossrefType "journal-article" @default.
- W2088294678 hasAuthorship W2088294678A5011892370 @default.
- W2088294678 hasAuthorship W2088294678A5014841232 @default.
- W2088294678 hasConcept C126322002 @default.
- W2088294678 hasConcept C141071460 @default.
- W2088294678 hasConcept C2776265017 @default.
- W2088294678 hasConcept C2776301958 @default.
- W2088294678 hasConcept C2776704044 @default.
- W2088294678 hasConcept C2778661090 @default.
- W2088294678 hasConcept C2778959117 @default.
- W2088294678 hasConcept C2779161974 @default.
- W2088294678 hasConcept C2780868729 @default.
- W2088294678 hasConcept C71924100 @default.
- W2088294678 hasConcept C90924648 @default.
- W2088294678 hasConceptScore W2088294678C126322002 @default.
- W2088294678 hasConceptScore W2088294678C141071460 @default.
- W2088294678 hasConceptScore W2088294678C2776265017 @default.
- W2088294678 hasConceptScore W2088294678C2776301958 @default.
- W2088294678 hasConceptScore W2088294678C2776704044 @default.
- W2088294678 hasConceptScore W2088294678C2778661090 @default.
- W2088294678 hasConceptScore W2088294678C2778959117 @default.
- W2088294678 hasConceptScore W2088294678C2779161974 @default.
- W2088294678 hasConceptScore W2088294678C2780868729 @default.
- W2088294678 hasConceptScore W2088294678C71924100 @default.
- W2088294678 hasConceptScore W2088294678C90924648 @default.
- W2088294678 hasIssue "5" @default.
- W2088294678 hasLocation W20882946781 @default.
- W2088294678 hasLocation W20882946782 @default.
- W2088294678 hasOpenAccess W2088294678 @default.
- W2088294678 hasPrimaryLocation W20882946781 @default.
- W2088294678 hasRelatedWork W1980752621 @default.
- W2088294678 hasRelatedWork W1988855938 @default.
- W2088294678 hasRelatedWork W2139393300 @default.
- W2088294678 hasRelatedWork W2366490876 @default.
- W2088294678 hasRelatedWork W2463643367 @default.
- W2088294678 hasRelatedWork W2981730791 @default.
- W2088294678 hasRelatedWork W2999314198 @default.
- W2088294678 hasRelatedWork W3022042949 @default.
- W2088294678 hasRelatedWork W3027698964 @default.
- W2088294678 hasRelatedWork W1603374058 @default.
- W2088294678 hasVolume "16" @default.
- W2088294678 isParatext "false" @default.
- W2088294678 isRetracted "false" @default.
- W2088294678 magId "2088294678" @default.
- W2088294678 workType "article" @default.